Vol 3, No 6 (December 19, 2014): Translational Lung Cancer Research (Personalized Therapy in Lung Cancer)

Special issue on personalized therapy in lung cancer

Update on third-generation EGFR tyrosine kinase inhibitors

Is the third generation EGFR TKIs the solution for making EGFR mutant NSCLC a curable disease?

EGFR, EGFR TKI, and EMSI: a never-ending story

Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance

Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor—resistant non-small cell lung cancer

Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer

Ceritinib as a promising therapy for ALK related diseases

Ceritinib—a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer

Necitumumab: a new therapeutic option for squamous cell lung cancer?

A critical question for cancer therapy: what new targets exist?

Targeting MET in NSCLC: looking for a needle in a haystack

Negative results of METLung study: an opportunity to better understand the role of MET pathway in advanced NSCLC

Targeting MET and EGFR in NSCLC—what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?

Angiogenesis and lung cancer: ramucirumab prolongs survival in 2^nd-line metastatic NSCLC

Nivolumab as first line monotherapy for advanced non-small cell lung cancer: could we replace first line chemotherapy with immunotherapy?

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer

A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors

A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer—the anti-PDL1 antibody—MEDI4736

Reflections on immune checkpoint inhibition in non-small cell lung cancer

Highlights in the 14^th Central European Lung Cancer Conference (CELCC)